Regulus Strengthens Executive Management Team with Addition of David Szekeres
as Chief Business Officer and General Counsel
-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience-
LA JOLLA, Calif., Feb. 4, 2014
LA JOLLA, Calif., Feb. 4, 2014 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
addition of David Szekeres to its executive management team as Chief Business
Officer and General Counsel. Most recently, Mr. Szekeres served as Deputy
General Counsel, Chief M&A Counsel and Assistant Secretary at Life
Technologies Corporation ("Life"), where he led more than fifty transactions
valued at over $30 billion, including the merger of Applied Biosystems and
Invitrogen in 2008 and the acquisition of Life by Thermo Fisher Scientific in
2013. During his tenure at Life, Mr. Szekeres was responsible for all legal
functions during a time of significant growth for the company in the areas of
corporate transactions, corporate governance, SEC reporting and compliance,
and was responsible for expanding Life's diagnostics business with several
strategic acquisitions. In his new role at Regulus, Mr. Szekeres will be
responsible for leading Regulus' business development, strategic planning and
legal efforts and will serve as a key member of its executive leadership team.
"We are very pleased to welcome David to our Regulus team at such an exciting
time for the company," said Kleanthis G. Xanthopoulos, Ph.D., President and
CEO of Regulus. "David's involvement with transformative strategic
transactions and overall operational experience at Life will add both depth
and strategic capabilities to our well rounded team as we continue to build
Regulus into a top-tier biopharmaceutical company. We are dedicated to RNA
therapeutics and to leading the discovery and development of a new and major
class of medicines targeting microRNAs."
Mr. Szekeres brings to Regulus over a decade of legal and deal-making
experience within the global life sciences industry. Prior to joining
Regulus, Mr. Szekeres held the position of Deputy General Counsel, Chief M&A
Counsel and Assistant Secretary at Life. Prior to joining Life, Mr. Szekeres
held positions of increasing responsibility at a number of prestigious law
firms, including Latham & Watkins LLP, O'Melveny & Myers LLP and Dechert LLP.
Mr. Szekeres began his career in the investment banking group at Robertson
Stephens. Mr. Szekeres is a member of the board of directors of Anochi
BioPharma and the San Diego chapter of the Association of Corporate Counsel.
Mr. Szekeres holds a B.A. from the University of California at Irvine and a
J.D. from Duke University.
"I am thrilled to be joining such an innovative company during a
transformative period in its growth," said David Szekeres, Chief Business
Officer and General Counsel of Regulus. "Regulus' commitment to innovation,
its cutting-edge science and its leadership in the microRNA field have enabled
the formation of significant strategic alliances and collaborations. I look
forward to working with the experienced management team to continue
strengthening these relationships and expanding Regulus' corporate development
efforts going forward."
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting
microRNAs.Regulus is uniquely positioned to leverage a mature therapeutic
platform that harnesses the oligonucleotide drug discovery and development
expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.,
which founded the company. Regulus has a well-balanced microRNA therapeutic
pipeline entering clinical development, an emerging microRNA biomarkers
platform to support its therapeutic programs, and a rich intellectual property
estate to retain its leadership in the microRNA field. Regulus intends to
focus its proprietary efforts on developing microRNA therapeutics for oncology
indications and orphan diseases and is currently advancing several programs
toward clinical development in oncology, fibrosis and metabolic diseases.
Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting
microRNA-122, for the treatment of chronic hepatitis C virus infection.
Regulus' commitment to innovation and its leadership in the microRNA field
have enabled the formation of strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi. In addition, the Company has established Regulus
microMarkers™, a research and development division focused on identifying
microRNAs as biomarkers of human disease, which is designed to support its
therapeutic pipeline, collaborators and strategic partners.
For more information, please visithttp://www.regulusrx.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.
or Liz Bryan, Spectrum Science, email@example.com, 202-955-6222 x2526
SOURCE Regulus Therapeutics Inc.
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, firstname.lastname@example.org, 858-202-6321
Press spacebar to pause and continue. Press esc to stop.